News

Germany’s Ifo index has reached a one year high, which hints at a more confident backdrop for companies planning to grow earnings rather than just defend margins. That creates an interesting setting for investors looking for earnings momentum combined with balance sheet discipline. This article examines three stocks from the Healthy high growth potential screener and explains why this blend of growth and financial strength may be appealing at this point. The stocks covered below are only a...

Why Iovance Biotherapeutics stock is back in focus after Q2 earnings Iovance Biotherapeutics (IOVA) is back on investor radars after its second quarter 2026 earnings. The company reported higher revenue and a reduced net loss, and it reaffirmed full year revenue guidance. The quarter was driven by Amtagvi and Proleukin sales, and by progress across Iovance Biotherapeutics pipeline programs, including new regulatory approvals and Fast Track designations for lifileucel in certain soft tissue...

Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.

The healthcare stock is now up more than 130% this year.

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

Moby summary of Iovance Biotherapeutics, Inc.'s Q2 2026 earnings call

Iovance Biotherapeutics Inc (IOVA) reports record Q2 2026 revenue of $99.3 million, driven by strong Amtagvi demand and all-time high gross margins of 56%.

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) is drawing attention ahead of its second quarter 2026 earnings report and corporate update scheduled for August 6, 2026, which will be presented alongside its first FDA-approved T cell therapy for solid tumors. See our latest analysis for Iovance Biotherapeutics. The latest pullback in Iovance Biotherapeutics, with a 1-day share price return down 13.22% and 7-day share price return down 18.44% to US$4.07, sits against a stronger backdrop that includes a 30-day...

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?